Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis

INTRODUCTION: Enzalutamide and abiraterone acetate (plus prednisone) are new hormonal treatments for metastatic castration-resistant prostate cancer (mCRPC). This study compared treatment duration, healthcare resource utilization (HRU), and treatment costs for chemotherapy-naïve mCRPC patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Neil M., Flanders, Scott C., Wilson, Samuel, Brown, Bruce A., Song, Yan, Yang, Hongbo, Lechpammer, Stanislav, Kassabian, Vahan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182626/
https://www.ncbi.nlm.nih.gov/pubmed/30191463
http://dx.doi.org/10.1007/s12325-018-0774-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182626/
https://www.ncbi.nlm.nih.gov/pubmed/30191463
http://dx.doi.org/10.1007/s12325-018-0774-1

Ejemplares similares